Melodiol Global Health (ASX:ME1DE) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Melodiol Global Health ROE % Adjusted to Book Value?

Melodiol Global Health's ROE % for the quarter that ended in Dec. 2023 was -1,939.87%. Melodiol Global Health's PB Ratio for the quarter that ended in Dec. 2023 was N/A. Melodiol Global Health's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was N/A.

Melodiol Global Health ROE % Adjusted to Book Value Historical Data

The historical data trend for Melodiol Global Health's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health ROE % Adjusted to Book Value Chart

Melodiol Global Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-71.48

-16.53

-40.07

-79.39

Melodiol Global Health Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial										-22.41	-31.24	-124.85	-173.35	-

Competitive Comparison of Melodiol Global Health's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Melodiol Global Health's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Melodiol Global Health's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Melodiol Global Health's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Melodiol Global Health's ROE % Adjusted to Book Value falls into.

Melodiol Global Health ROE % Adjusted to Book Value Calculation

Melodiol Global Health's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-575.19%	/	N/A
	=	N/A

Melodiol Global Health's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-1,939.87%	/	N/A
	=	N/A

Melodiol Global Health ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Melodiol Global Health (ASX:ME1DE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (ASX:ME1DE) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

COPHF:USA

Address

145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009

Website

https://www.cresopharma.com

Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (ASX:ME1DE) Headlines

No Headlines